Mikko I. Kettunen

TL;DR: In lymphoma-bearing mice injected intravenously with hyperpolarized [1-13C]pyruvate, it is shown that the lactate dehydrogenase–catalyzed flux of 13C label between the carboxyl groups of pyruvates and lactate in the tumor can be measured using 13C magnetic resonance spectroscopy and spectroscopic imaging, and that this flux is inhibited within 24 h of chemotherapy.

TL;DR: It is shown that a soluble form of VEGFR-3 is a potent inhibitor of Vascular endothelial growth factor (VEGF)-C and VEGF-D signaling, and when expressed in the skin of transgenic mice, it inhibits fetal lymphangiogenesis and induces a regression of already formed lymphatic vessels, though the blood vasculature remains normal.

TL;DR: Tissue pH can be imaged in vivo from the ratio of the signal intensities of hyperpolarized bicarbonate and 13CO2 following intravenous injection of hyperPolarized H13CO3-.

TL;DR: By using virus-mediated VEGF-C gene therapy, the results suggest that growth factor gene therapy is applicable to human lymphedema and provide a paradigm for other diseases associated with mutant receptors.

TL;DR: This study compares, for the first time, angiogenesis and lymphangiogenesis induced by gene transfer of different human VEGFs, and shows that VEGF-D is the most potent member when delivered via an adenoviral vector into skeletal muscle.